Obesity, inflammation and endothelial dysfunction;Obesidad, inflamación y disfunción endotelial

Revista Espanola de Obesidad

Volumn 4, Issue 4, 2006, Pages 195-204

  Cachofeiro, Victoria ^a   Miana, María ^a   Martín Fernández, Beatriz ^a   De Las Heras, Natalia ^a   Lahera, Vicente ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOCRINE GLAND; ENDOTHELIAL DYSFUNCTION; INFLAMMATION; OBESITY; REVIEW;

EID: 33747789844     PISSN: 16966112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10: 97S-104S.
2. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-9.
3. Caballero AE. Endotelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res 2003; 11: 1278-89.
4. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-49.
5. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288: H203-41.
6. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
7. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-9.
8. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002; 25: 1320-5.
9. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13.
10. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med 1993; 44: 121-31.
11. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9.
12. Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T. Molecular mechanisms for vascular injury in metabolic syndrome. Drugs Exptl Clin Res 2005; XXXI: 123-9.
13. Medell MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross-sectional study. Br Med J 1996; 312: 1061-5.
14. Visser M, Boute LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. J Am Med Assoc 1999; 282: 2131-5.
15. Visser M, Bouter LM, McQuillan GM, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics 2001; 107: 1-6.
16. Nicoletti G, Giugliano G, Pontillo A, Cioffi M, D'Andrea F, Giugliano D, et al. Effect of a multidisciplinary program of weight reduction on endothelial function in obese women. J Endocrinol Invest 2003; 26: RC5-8.
17. Heibroee LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001; 21: 968-70.
18. Kopp AH, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidity obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-7.
19. Giugliano G, Nicoletti G, Grella E, Giugliano F, Esposito K, Scuderi N, et al. Effect of liposuction insulin resistance and vascular inflammatory markers in obese women. Br J Plast Sur 2004; 57: 1904.
20. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350: 2549-57.
21. Trayhurn P, Wood IS. Adipokines: Inflammation and the pleitropic role of white adipose tissue. Br J Nutr 2004; 92: 347-55.
22. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
23. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes 2003; 27: S25-8.
24. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 6714.
25. Després JP. Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes 2003; 27: S22-4.
26. Lolmede K, Durant de Saintfront V, Galizky J, Lanfontan M, Bouloumie A. Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes. Int J Obes 2003; 27: 1187-95.
27. Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1β and tumor necrosis factor α stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94: 1561-7.
28. Höpfl G, Ogunshola O, Gassmann M. HIFs and tumors. Causes and consequences. Am J Physiol 2004; 286: R608-23.
29. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
30. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
31. Lau D, Yan H, Abdel-Hafez M, Kermouni A. Adipokines and the paracrine control of their production in obesity and diabetes. Int J Obes 2002; 26: S111.
32. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation 2002; 106: 1904-5.
33. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
34. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001; 33: 95-102.
35. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
36. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-100.
37. Schafer K, Halle M, Goeschen C, Dellas C, Pynn M, Loskutoff DJ, et al. Leptin promotes vascular remodelling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004; 24: 112-7.
38. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001; 276: 37402-8.
39. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6.
40. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to Cq1, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
41. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 256: 79-83.
42. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
43. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulate cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316: 924-9.
44. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
45. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-9.
46. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, et al. Adiponectin acts as an endogenous antithrombotic factor. Arteriocler Thromb Vasc Biol 2006; 26: 224-30.
47. Rea R, Donnelly R. Resistin: an adypocite-derived hormone. Has it a role in diabetes and obesity? Diabet Obes Metab 2004; 6: 163-70.
48. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
49. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signalling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-8.
50. Bhagat K, Vallance P. Inflammatory cytokines impairs endothelium- dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-7.
51. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissue of obese human. Endocrinology 2004; 145: 2273-82.
52. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator-1 and haemostasis in obesity. Proc Nutr Soc 2001; 60: 341-7.
53. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med 1999; 340: 448-54.
54. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilatation and nitric oxide production. Diabetes 2000; 49: 1231-8.
55. Haller H. Endothelial function: general considerations. Drugs 1997; 53: 1-10.
56. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol. 1999; 31: 6174.
57. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-51.
58. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
59. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117: 499-507.
60. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscl Thromb Vasc Biol 2000; 20: 2094-9.
61. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-8.
62. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, et al. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003; 126: 1886-91.
63. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-9.
64. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-6.
65. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Stood 1993; 82: 513-20.
66. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator-1 expression and activity in human aortic endothelial cells. Circulation 2003; 107: 398-404.
67. Libby P, Simon DI. Inflammation and thrombosis: the clot thicknes. Circulation 2001; 103: 1718-20.
68. Martínez-González J, Llorent-Cortés V, Badimón L. Biología celular y molecular de las lesiones ateroscleróticas. Rev Esp Cardiol 2001; 54: 218-31.
69. Newby AC, Zaltsman AB. Fibrous cap formation or destruction: the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res 1999; 41: 345-60.
70. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-8.
71. Moreno PR, Fuster V. The year in atherothrombosis. JACC 2004: 11: 2099-110.
72. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999; 41: 402-17.
73. Dzau V. Pathobiology of atherosclerosis and plaque complications. Am Heart J, 1994; 128: 1300-4.
74. Naghavi M, John R, Naguib S, Siadaty MS, Grasu R, Kurian KC, et al. pH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis 2002; 164: 27-35.
75. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109(25 Suppl 1): IV6-19.
76. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
77. Thompson S, Kienaast J, Pyke S, Haverkate F, Van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
78. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
79. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-47.
80. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-79.
81. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.